Literature DB >> 35333927

WGCNA and molecular docking reveal key hub genes and potential natural inhibitor in interstitial cystitis/bladder pain syndrome.

Kuiqing Li1, Cong Lai1, Cheng Liu1, Zhuohang Li1, Kaixuan Guo1, Kewei Xu2.   

Abstract

INTRODUCTION AND HYPOTHESIS: The etiology and treatment of interstitial cystitis/bladder pain syndrome are still controversial. The purpose of this study is to determine the key genes and specific regulatory pathways related to it and to find potential drug-active components through integrated bioinformatics.
METHODS: The data set GSE11783 was downloaded from GEO database. The modules significantly related to interstitial cystitis/bladder pain syndrome were identified by weighted correlation network analysis. The genes in the key modules were analyzed by functional enrichment and protein interaction by Cytoscape software, and finally the core hub genes were screened. Furthermore, the molecular docking verification of active components and key proteins was carried out by using AutoDock Vin software.
RESULTS: Among the 14 modules derived from WGCNA, turquoise module had the highest correlation with IC/BPS (r = 0.85, P < 0.001). The genes in the module were mainly enriched in the biological processes such as the interaction between cytokines and cytokine receptors and chemokine signaling pathway. The genes in the related modules of differentially expressed genes and WGCNA traits were intersected to obtain the core hub genes. Protein-protein interaction network analysis showed that the key genes were upregulated genes CCR7 and CCL19. In terms of molecular docking, triptolide, the active component in the traditional anti-inflammatory drug Tripterygium wilfordii, can form effective molecular binding with both core hub genes.
CONCLUSIONS: Our study identified the core hub genes CCR7 and CCL19, which acted as essential components in interstitial cystitis/bladder pain syndrome. Furthermore, CCR7 and CCL19 can form effective binding with triptolide, which will provide new insights into the development of new therapies for interstitial cystitis/bladder pain syndrome.
© 2022. The International Urogynecological Association.

Entities:  

Keywords:  CCL19; CCR7; Interstitial cystitis/bladder pain syndrome; Molecular docking; Triptolide; Weighted gene co-expression network analysis

Mesh:

Substances:

Year:  2022        PMID: 35333927     DOI: 10.1007/s00192-022-05113-9

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   1.932


  2 in total

1.  Triptolide induces anti-inflammatory cellular responses.

Authors:  Ranyia Matta; Xianxi Wang; Hui Ge; William Ray; Leif D Nelin; Yusen Liu
Journal:  Am J Transl Res       Date:  2009-03-05       Impact factor: 4.060

2.  Triptolide inhibits CCR5 expressed in synovial tissue of rat adjuvant-induced arthritis.

Authors:  Wang Yifan; Wei Dengming; Lai Zheng; Le Yanping; Shen Junkan
Journal:  Pharmacol Rep       Date:  2007 Nov-Dec       Impact factor: 3.024

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.